Company intelligence / Profile preview

Pykus Therapeutics

Cambridge, Massachusetts, United Statespykustherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Pykus Therapeutics has completed enrollment for its pilot clinical study of PYK‑2101, a novel biodegradable hydrogel retinal sealant designed to eliminate the need for intraocular gas and face-down positioning after retinal detachment surgery. Interim results are expected in Q2 2025. The device aims to improve both visual and anatomical outcomes compared to current standards of care. The product remains investigational and has not yet received FDA approval or clearance.

Therapeutic areas: Ophthalmology
Modalities: DeviceHydrogel-based drug delivery therapyBiodegradable polymer device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

PYK-2101

Phase 1

Indications: Retinal detachment

Partnerships

Mass Eye and Ear / Mass General Brigham at Harvard Medical School (technology licensed from this institution)

Beyond the preview

Go deeper on Pykus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pykus Therapeutics.

Explore the full profile